{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:28:25Z","timestamp":1793093305484,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.7759\/cureus.81084","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T14:58:05Z","timestamp":1742828285000},"source":"Crossref","is-referenced-by-count":1,"title":["Desensitization to Tocilizumab in a Patient With Juvenile Idiopathic Arthritis"],"prefix":"10.7759","author":[{"given":"Rosalaura V","family":"Villarreal-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana E","family":"Cadenas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"V\u00e1zquez-Nungaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana V","family":"Villarreal-Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Vidal-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103086","article-title":"Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"21","author":"Storwick JA","year":"2022","unstructured":"Storwick JA, Brett AC, Buhler K, et al.. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: a systematic review and meta-analysis. Autoimmun Rev. 2022, 21:103086. 10.1016\/j.autrev.2022.103086","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00629-8","article-title":"Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches","volume":"19","author":"Zaripova LN","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021, 19:135. 10.1186\/s12969-021-00629-8","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2021.7953","article-title":"Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review","volume":"36","author":"Adrovic A","year":"2021","unstructured":"Adrovic A, Yildiz M, K\u00f6ker O, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review. Arch Rheumatol. 2021, 36:146-57. 10.46497\/ArchRheumatol.2021.7953","journal-title":"Arch Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13114","article-title":"Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases","volume":"30","author":"Soyer O","year":"2019","unstructured":"Soyer O, Demir S, Bilginer Y, et al.. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol. 2019, 30:833-40. 10.1111\/pai.13114","journal-title":"Pediatr Allergy Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13142","article-title":"Management of hypersensitivity reactions to tocilizumab","volume":"48","author":"T\u00e9tu P","year":"2018","unstructured":"T\u00e9tu P, Hamelin A, Moguelet P, Barbaud A, Soria A. Management of hypersensitivity reactions to tocilizumab. Clin Exp Allergy. 2018, 48:749-52. 10.1111\/cea.13142","journal-title":"Clin Exp Allergy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247291","article-title":"Hypersensitivity to biological treatments in juvenile idiopathic arthritis: how should it be managed?","volume":"11","author":"Kasap Cuceoglu M","year":"2022","unstructured":"Kasap Cuceoglu M, Basaran O, Soyer O, Ozen S. Hypersensitivity to biological treatments in juvenile idiopathic arthritis: how should it be managed?. J Clin Med. 2022, 11:7291. 10.3390\/jcm11247291","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard M","year":"2017","unstructured":"Picard M, Galv\u00e3o VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017, 5:600-9. 10.1016\/j.jaip.2016.12.001","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe GA","year":"2018","unstructured":"Isabwe GA, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018, 142:159-170.e2. 10.1016\/j.jaci.2018.02.018","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1457490","article-title":"Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis","volume":"29","author":"Yasuoka R","year":"2019","unstructured":"Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol. 2019, 29:324-7. 10.1080\/14397595.2018.1457490","journal-title":"Mod Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2020.06.007","article-title":"[Rapid desensitisation to tocilizumab in systemic idiopathic juvenile arthritis]","volume":"94","author":"Villarreal Gonz\u00e1lez R","year":"2021","unstructured":"Villarreal Gonz\u00e1lez R, Gonz\u00e1lez D\u00edaz S, de Lira Quezada C, Mac\u00edas Weinmann A, Acu\u00f1a Ortega N. [Rapid desensitisation to tocilizumab in systemic idiopathic juvenile arthritis]. An Pediatr (Engl Ed). 2021, 94:180-1. 10.1016\/j.anpedi.2020.06.007","journal-title":"An Pediatr (Engl Ed)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0314","article-title":"Successful slow desensitization to tocilizumab in a 15-year-old patient","volume":"28","author":"Cansever M","year":"2018","unstructured":"Cansever M, \u015eahin N, Dursun I, Geyik C, D\u00fc\u015f\u00fcnsel R, Bekta\u015f Kut F, Tahan F. Successful slow desensitization to tocilizumab in a 15-year-old patient. J Investig Allergol Clin Immunol. 2018, 28:436-8. 10.18176\/jiaci.0314","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342755-desensitization-to-tocilizumab-in-a-patient-with-juvenile-idiopathic-arthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T14:58:07Z","timestamp":1742828287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342755-desensitization-to-tocilizumab-in-a-patient-with-juvenile-idiopathic-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.81084","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}